Potassium channel openers — novel triggers of aura and migraine

Alan M. Rapoport; Richard B. Lipton

doi:10.1038/s41582-021-00517-5

Potassium channel openers — novel triggers of aura and migraine

Alan M. Rapoport, Richard B. Lipton

Neurology

Research output: Contribution to journal › Comment/debate › peer-review

3 Scopus citations

Original language	English (US)
Pages (from-to)	397-398
Number of pages	2
Journal	Nature Reviews Neurology
Volume	17
Issue number	7
DOIs	https://doi.org/10.1038/s41582-021-00517-5
State	Published - Jul 2021

ASJC Scopus subject areas

Clinical Neurology
Cellular and Molecular Neuroscience

Access to Document

10.1038/s41582-021-00517-5

Cite this

@article{36ab6b9d1eca410a8a550c519730861a,

title = "Potassium channel openers — novel triggers of aura and migraine",

author = "Rapoport, {Alan M.} and Lipton, {Richard B.}",

note = "Funding Information: A.M.R. serves as an advisor for AbbVie, Amgen, Biohaven, Cala Health, Novartis, Satsuma, Teva Pharmaceutical Industries, Theranica, Xoc and Zosano; he is on the speaker bureau of AbbVie, Amgen, Biohaven, Lundbeck and Teva Pharmaceutical Industries. R.B.L. receives research support from the NIH and FDA as well as the National Headache Foundation and the Marx Foundation. He also receives research support from Allergan/Abbvie, Amgen, Biohaven Holdings, Eli Lilly and Electrocore. He receives personal fees as a consultant or advisor from Allergan/Abbvie, Amgen, Biohaven Holdings, Dr. Reddy{\textquoteright}s, GlaxoSmithKline, Grifols, Impel NeuroPharma, Lundbeck, Merck, Novartis and Teva Pharmaceuticals. He holds stock or options in Biohaven Holdings and CtrlM Health. In addition, he receives royalties for Wolff{\textquoteright}s Headache 7th and 8th Edition.",

year = "2021",

month = jul,

doi = "10.1038/s41582-021-00517-5",

language = "English (US)",

volume = "17",

pages = "397--398",

journal = "Nature Clinical Practice Neurology",

issn = "1759-4758",

publisher = "Nature Publishing Group",

number = "7",

}

TY - JOUR

T1 - Potassium channel openers — novel triggers of aura and migraine

AU - Rapoport, Alan M.

AU - Lipton, Richard B.

N1 - Funding Information: A.M.R. serves as an advisor for AbbVie, Amgen, Biohaven, Cala Health, Novartis, Satsuma, Teva Pharmaceutical Industries, Theranica, Xoc and Zosano; he is on the speaker bureau of AbbVie, Amgen, Biohaven, Lundbeck and Teva Pharmaceutical Industries. R.B.L. receives research support from the NIH and FDA as well as the National Headache Foundation and the Marx Foundation. He also receives research support from Allergan/Abbvie, Amgen, Biohaven Holdings, Eli Lilly and Electrocore. He receives personal fees as a consultant or advisor from Allergan/Abbvie, Amgen, Biohaven Holdings, Dr. Reddy’s, GlaxoSmithKline, Grifols, Impel NeuroPharma, Lundbeck, Merck, Novartis and Teva Pharmaceuticals. He holds stock or options in Biohaven Holdings and CtrlM Health. In addition, he receives royalties for Wolff’s Headache 7th and 8th Edition.

PY - 2021/7

Y1 - 2021/7

UR - http://www.scopus.com/inward/record.url?scp=85106532120&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85106532120&partnerID=8YFLogxK

U2 - 10.1038/s41582-021-00517-5

DO - 10.1038/s41582-021-00517-5

M3 - Comment/debate

C2 - 34040232

AN - SCOPUS:85106532120

SN - 1759-4758

VL - 17

SP - 397

EP - 398

JO - Nature Clinical Practice Neurology

JF - Nature Clinical Practice Neurology

IS - 7

ER -

Potassium channel openers — novel triggers of aura and migraine

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this